

Prevalence of Microalbuminuria and Dyslipidemia in Polycystic Ovarian Disease Patients

SASMITA MISHRA¹, M MANJU², SURYA R PRIYA³, SOWMIYA MURALI⁴, SRI N SUDHARDHAN⁵

ABSTRACT

Introduction: Polycystic Ovarian Disease (PCOD) is the most common hormonal disorder in women. PCOD is associated with an increase in subclinical atherosclerotic disease and endothelial dysfunction. The altered endothelial function and early endothelial damage can be assessed by Urinary Albumin Excretion (UAE), a marker of an atherogenic background. Dyslipidaemia is a very common metabolic abnormality in women with PCOD due to elevated androgen level and insulin resistance. As evidenced from previous studies PCOD patients are at an increased cardiovascular risk compared with the age matched controls.

Aim: To evaluate the prevalence of microalbuminuria and dyslipidaemia in premenopausal PCOD patients compared to normal premenopausal women.

Materials and Methods: The present study was carried out at Department of Biochemistry, Aarupadai Veedu Medical College and Hospital Puducherry, India. A total of 40 diagnosed PCOD patients (according to Rotterdam criteria) of premenopausal age (21 to 42 years) and 40 age and sex matched controls (22 to 43 years) without PCOD were included in the study. All subjects had undergone measurement of height, weight and Blood Pressure (BP), and detailed systemic examination. Fasting

plasma glucose, serum cholesterol, Triglycerides (TG), and High Density Lipoprotein-Cholesterol (HDLc) were estimated by using commercially available kits in automated Chemistry Analyser (ChemWell). Low Density Lipoprotein-Cholesterol (LDLc) and Very Low Density Lipoprotein-Cholesterol (VLDLc) were calculated by Friedwald's equation. Urine microalbumin was estimated by Latex turbidimetry method using semi Autoanalyser BIOTRON BTR830. Urine creatinine was estimated by commercial kit in Autoanalyser. Albumin-Creatinine Ratio (ACR) value more than 30 mg/g was taken as microalbuminuria positive. Student's t-test and SPSS version 16.0 were used for statistical analysis.

Results: Out of 40 PCOD patients 21 patients were having microalbuminuria and out of 40 controls only two were having microalbuminuria. Routine biochemical investigations registered a significant rise of fasting plasma glucose, TG, TC, LDLc and VLDLc in PCOD patients, incomparison with controls ($p=0.02$ for LDLc and $p<0.001$ for all other parameters). Significant alterations in lipid parameters showed association of dyslipidaemia in PCOD patients.

Conclusion: In the present study prevalence of microalbuminuria and dyslipidaemia are more in patients with polycystic ovary disease than age matched controls so these parameters can be frequently estimated to prevent complications in PCOD patients.

Keywords: Androgen, Hyperlipidemia, Premenopausal age, Urine microalbumin

INTRODUCTION

Polycystic ovarian disease is the most common hormonal disorder in women worldwide, with an estimated prevalence between 4 and 8%, and one of the most common cause of ovulatory infertility [1]. PCOD is a heterogeneous disorder with unknown aetiology in which ovaries produces excess androgens and is associated with insulin resistance [2]. PCOD was diagnosed if any two of the following three criteria (Rotterdam criteria) were present after excluding other possible causes: i) oligo and/or anovulation; ii) clinical and/or biochemical signs of hyperandrogenism; and iii) polycystic ovaries on ultrasonography [3].

Insulin resistance is an important aspect of PCOD and may contribute to an increased risk of developing Type 2 diabetes and coronary heart disease [4].

The PCOD patients have endothelial dysfunction which leads to increase incidence of subclinical atherosclerotic disease [5,6]. Altered insulin regulation of endothelial Nitric Oxide (NO) synthesis leads to decreased NO production and impaired NO dependant vasodilatation which may be a cause for endothelial dysfunction [6,7]. The altered endothelial function and early endothelial damage can be assessed by UAE, a marker of an atherogenic background [8]. Epidemiologic and clinical evidence shows that microalbuminuria is associated with an increased cardiovascular mortality [9,10]. Many studies have shown that people having very low levels of microalbuminuria only without chronic diseases like renal dysfunction, hypertension, or diabetes suffer from coronary

artery disease and death [11,12]. Dyslipidaemia is a very common metabolic abnormality in women with PCOD, with a prevalence of up to 70% [13]. Women with PCOD are usually obese and have elevated androgen level leading to dyslipidaemia [14].

Because of insulin resistance, they are expected to be at increased risk for dyslipidaemia [13]. Due to presence of cardiovascular risk factors like dyslipidaemia, insulin resistance, and endothelial dysfunction, PCOD patients are at an increased cardiovascular risk compared with the age matched controls [15]. Some studies had shown that women with PCOD have increased risk for cardiovascular events not related to Body Mass Index (BMI) [16,17]. Very few Indian studies are there and due to the increasing prevalence of PCOD, we decided to explore the association of microalbuminuria and dyslipidaemia in PCOD patients and to compare that with age matched controls [12,14].

MATERIALS AND METHODS

The present comparative cross sectional hospital based study was carried out at Biochemistry Department, Aarupadaveedu Medical College and Hospital, Puducherry, India from April 2016 to July 2016. The patients attended Obstetric and Gynaecology Out Patient Department and diagnosed as PCOD patient were selected for the study. A total of 40 diagnosed PCOD patients (according to Rotterdam criteria) of premenopausal age (21 to 40 years) and 40 age matched controls were taken for the study [3].

Controls were selected among the female patients attending the OPD of Medicine and Obstetric and Gynaecology department (who came for some common acute illness like viral fever, diarrhoea, dysmenorrhoea) and also the faculties of AV Medical College and Hospital. The study group (both cases and control) was selected after excluding the exclusion criteria.

Sample size was calculated with the help of software based on other similar Study [18]. Both Scientific committee and Ethical committee clearance was taken and informed consent was taken from the study population.

The PCOD was diagnosed according to the Rotterdam criteria [3]. The patients having two or more of the following criteria were defined as PCOD:

- History of oligo and/or anovulation in reproductive age.
- Clinical and/or biochemical signs of hyperandrogenism: hirsutism score of >6 and/or high total testosterone level.
- Typical ovarian imaging of polycystic ovaries on ultrasound: multiple follicles in each ovary measuring 2-9 mm in diameter and/or increased ovarian volume (>10 mL).

Inclusion Criteria

All newly diagnosed cases of PCOD from Department of Obstetrics and Gynaecology in the age group 21 to 40 years were taken as cases. Apparently healthy premenopausal age (21 to 40 years) women attending medicine and obstetrics and gynaecology OPD and staff of AVMC were taken as control. Controls were having regular menstrual cycles and with no clinical features of hyperandrogenism, thereby excluding the diagnosis of PCOD in this group.

Exclusion Criteria

Women with diabetes mellitus, hyperprolactinaemia, thyroid, renal, hepatic, adrenal and cardiac dysfunction were excluded from the study. Pregnancy, urinary tract infection, and those on lipid-lowering drugs, anti-hypertensive agents were also excluded from the study.

Already known microalbuminuria and dyslipidemia cases were excluded from study group.

Height and weight were measured and BMI was calculated by the formula: weight in kg/height in m² [19]. Blood pressure of the study subjects was measured by standardised methods. Both cases and controls were subjected to estimation of biochemical parameters. A 5 mL of venous blood was collected from anterior cubital vein of left hand in fluoride tube for glucose and clot activator tubes for other estimations after an overnight fast. Fasting plasma glucose, serum cholesterol, TG, and HDLc were estimated by using commercially available kits in automated Chemistry analyser (Chemwell). Serum LDLc and VLDLc were calculated by Friedewald's equation {LDLc=Total Cholesterol-(HDLc+VLDLc), Where VLDLc=TG/5} [20].

Morning fasting urine samples were collected for micro albumin and creatinine estimation. Urine micro albumin was analysed in semi autoanalyser-BIOTRON BTR 830 and creatinine was estimated by auto analyser. ACR value more than 30 mg/g was taken as microalbuminuria positive.

STATISTICAL ANALYSIS

All the results were subjected to statistical analysis by the Statistical Package for the Social Sciences (SPSS) software 16.0 version. Student t-test was used for comparison among variables in two groups. A p-value less than 0.05 were taken as significant.

RESULTS

The age distribution of patients and controls were between 21-40 years [Table/Fig-1]. BMI of PCOD patients were found to be more than the controls (p<0.001) [Table/Fig-1]. Routine biochemical investigations registered a significant rise of fasting plasma glucose, TG, total cholesterol, LDLc and VLDLc in PCOD patients, in comparison with controls (p=0.02 for LDL cholesterol and p<0.001 for all other parameters) [Table/Fig-2]. Out of 40 PCOD patients 21 patients were having micro albuminuria and out of 40 controls only two were having micro albuminuria [Table/Fig-3].

	Age in years	BMI (Kg/m ²)	SBP (mm Hg)	DBP (mm Hg)	FBS (mg/dL)	Urea (mg/dL)	Creatinine (mg/dL)
Control group n=40							
Mean±SD	32.8±5.5	22.9±4.1	116±8.7	73±6.4	95.9±10.9	22.9±5.9	0.75±0.2
Range	22-43	17.1-32	90-130	60-80	59-110	14-45	0.4-1.6
PCOD group n=40							
Mean±SD	30.4±6.3	24.9±3.3	119±8.7	73±5.6	150.1±59.6	24.2±9.9	0.91±0.3
Range	21-42	18.4-35.7	100-130	60-80	53-324	12.0-69	0.4-2.6
Comparison between two groups							
Control vs. PCOD patient	p=0.07	p=0.02	p=0.12	p=1	p<0.001	p=0.2	p=0.01
	ns	*	ns	ns	***	ns	*

[Table/Fig-1]: Comparison of BMI and serum biochemical parameters in control and PCOD patients.

ns=not significant; *significant; ***highly significant

Data analysis was done by SPSS Software 16.0 version. Student's t-test was used for comparison among variables in two groups. A p-value less than 0.05 was taken as significant.

BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; FBS: Fasting blood sugar; PCOD: Polycystic ovarian disease


	TC (mg/dL)	TG (mg/dL)	HDLc (mg/dL)	VLDLc (mg/dL)	LDLc (mg/dL)	UACR (mg/g)
Control group n=40						
Mean±SD	183.6±24.6	103.9±42.6	37.6±6.62	20.77±8.48	125.3±25.8	13.82±8.9
Range	122-240	54-261	23-48	11.0-52	76-186	3.0-41
PCOD group n=40						
Mean±SD	216.5±38	170.9±84	40.92±10.4	34.1±16.7	141.4±37.2	47.17±39.8
Range	162-304	82-456	23-60	16-91	69-208	5-150
Comparison between two groups						
Control vs. PCOD patients	p<0.001	p<0.001	p=0.09	p<0.001	p=0.02	p<0.001
	***	***	Ns	***	*	***

[Table/Fig-2]: Comparison of lipid profile and ACR in control and PCOD patients.

ns=not significant; *significant; ***highly significant

Data analysis was done by SPSS Software 16.0 version. Student's t-test was used for comparison among variables in two groups. A p-value less than 0.05 were taken as significant.


TC: Total cholesterol; TG: Triglyceride; HDLc: High density lipoprotein cholesterol; LDLc: Low density lipoprotein cholesterol; VLDLc: Very low density lipoprotein cholesterol; UACR: Urine albumin creatinine ratio; PCOD: Polycystic ovarian disease



[Table/Fig-3]: Comparing microalbuminuria in control and PCOD patients.

MA+ Microalbuminuria Positive
 Out of 40 controls only 2 were MA+
 Out of 40 PCOD Patients 21 were MA+

Significant alterations in lipid parameters showed association of dyslipidaemia in PCOD patients. There was a small rise in serum HDLc in PCOD patients (Mean±SD is 37.6±6.62 for controls compared to cases which is 40.92±10.4 and the p-value is 0.09) than in controls but it was not significant [Table/Fig-4]. ACR was more in PCOD patients than controls ($p < 0.001$, which was highly significant) [Table/Fig-2].



[Table/Fig-4]: Comparing lipid profile in control and PCOD patients.

TC: Total cholesterol (Mean±SD 183.6±24.6 for controls and 216.5±38 for PCOD patients); TG: Triglyceride (Mean±SD 103.9±42.6 for controls and 170.9±84 for PCOD patients); HDLc: High density lipoprotein cholesterol (Mean±SD 37.6±6.62 for controls and 40.92±10.4 for PCOD patients); VLDLc: Very low density lipoprotein cholesterol (Mean±SD 20.77±8.48 for controls and 34.1±16.7 for PCOD patients); LDLc: Low density lipoprotein cholesterol (Mean±SD 125.3±25.8 for controls and 141.4±37.2 for PCOD patients)

DISCUSSION

Microalbuminuria is excretion of albumin in urine in the range of 20-200 µg/minute. It is often expressed as ACR and the range is 30-300 mg of albumin/g of creatinine in urine [21].

The PCOD patients usually have Insulin resistance which appears to play a key role in the development of endothelial damage [22]. Microalbuminuria and Leakage of other plasma macromolecules enhances inflammatory reactions which may initiates the process of atherosclerosis and increases the risk of CVDs. Some studies showed that the predictive power of microalbuminuria levels for cardiovascular risk were not dependent on other cardiovascular risk factors like diabetes and or hypertension but also present in otherwise healthy individuals [23,24]. Lowering albuminuria could decrease CVDs in PCOD patients [25]. The Framingham Heart Study found that six year risk of CVD was three fold higher in non-hypertensive, non-diabetic subjects with urinary ACR above the gender specific median than in those with urinary ACR below the median [26]. Hyperinsulinaemia often associated with PCOD may cause glomerular hypertension and increase filtration leading to increased albumin ultrafiltration and excretion [27]. Some studies

got a clear association between more severe insulin resistance and microalbuminuria [28].

In present study, we got ACR value of 47.17±39.8 mg/g for PCOD patients compared to 13.82±8.9 mg/g for normal controls which is highly significant ($p < 0.001$). This is similar to the report of Ganie MA et al., and Duleba AJ et al., [4,29].

The PCOD patients are usually obese and have elevated androgen and insulin levels, all these predispose them to develop dyslipidaemia. Moreover, they are insulin resistant too. Insulin resistance and hyperinsulinaemia are also associated with dyslipidaemia which initiates atherosclerosis [30,31]. Increased insulin concentrations increases VLDL synthesis, leading to hypertriglyceridaemia [32]. Progressive elimination of lipid and apolipoproteins from the VLDL particle leads to an increased formation of intermediate-density lipoprotein and LDL, both of which are atherogenic. Apart from hypertension and dyslipidaemia insulin is an independent risk factor for development of atherosclerosis. Insulin increases cholesterol transport into arteriolar smooth muscle cells and increases endogenous lipid synthesis by these cells. Insulin also stimulates the proliferation of arteriolar smooth muscle cells, augments collagen synthesis in the vascular wall, increases the formation of lipid plaques, and stimulates the production of various growth factors [30].

Insulin resistance present in PCOD patients appears to be associated with lipid abnormalities and atherosclerotic CVD. As a consequence, insulin resistance contributes to, high TG and high LDL. Reverse transport of cholesterol to liver is impaired, leading to its reduced excretion [33]. Therefore, these patients have increased serum levels of total cholesterol.

The PCOD women have increased androgen which is associated with increased hepatic lipase activity [34,35]. Hepatic lipase converts more buoyant HDLc to smaller denser HDLc which can be taken up by liver decreasing HDLc level and it also converts more buoyant LDLc to smaller denser LDLc both are risk factors for CVD [36]. Thus, dyslipidaemia may precede the association with insulin resistance and increased risk for CVD. So preventing dyslipidemia in PCOD patients CVD can be prevented.

In the present study TG, TC, LDLc and VLDLc in PCOS patients were significantly higher in comparison with controls ($p = 0.02$ for LDLc cholesterol and $p < 0.001$ for all other parameters). Significant alterations in lipid parameters show association of dyslipidaemia in PCOS patients. There was a small rise in serum HDLc in PCOS patients than controls but it is not significant. This study finding is similar to the study of Ambiger S, Kim JJ and Choi YM and Kaviprasanna S et al., [37-39].

Hence, in PCOD women microalbuminuria and serum lipid profile can be done early and at frequent intervals to prevent the progression and complications of the disease.

LIMITATION

Limitations of present study were small sample size. We could not measure the extended lipid profile which is more reliable. Sample (blood) taken from the subjects once only.

CONCLUSION

Prevalence of microalbuminuria and dyslipidaemia are more in patients with PCOD patients than in age matched controls. PCOD women should be evaluated for status of serum lipids and microalbuminuria at frequent intervals to prevent the complications and which aids in the management also.

REFERENCES

- [1] Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223-36. Available from: <https://www.uptodate.com/contents/clinical-manifestations-of-polycystic-ovary-syndrome-in-adults/abstract/1>
- [2] Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-49.

- [3] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril*. 2004;81:19-25.
- [4] Ganie MA, Farooqui KJ, Bhat MA, Mir MM, Shah ZA, Douhath S, et al. Pattern of urinary albumin excretion in normotensive young and adolescent Indian women with polycystic ovary syndrome. *Indian Endocrinol Metab*. 2012;16(2):277-82.
- [5] Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin 1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. *J Clin Endocrinol Metab*. 2001;86:4666-73.
- [6] Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM. Altered vascular function in young women with polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2002;87:742-46.
- [7] Lakhani K, Constantinovici N, Purcell WM, Fernando R, Hardiman P. Internal carotid-artery response to 5% carbon dioxide in women with polycystic ovaries. *Lancet*. 2000;356:1166-67.
- [8] Feldt-Rasmussen B. Microalbuminuria, endothelial dysfunction and cardiovascular risk. *Diabet Metabol (Paris)*. 2000;26:64-66.
- [9] Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA*. 2001;286:421-26.
- [10] De Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. *J Am Soc Nephrol*. 2006;17:2100-05. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/16825327?dopt=Abstract>
- [11] Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. *Circulation*. 2004;110:32-35.
- [12] Sukhija R, Aronow WS, Kakar P, Garza L, Sachdeva R, Sinha A, et al. Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus. *Am J Cardiol*. 2006;98:279-81.
- [13] Legro RS, Kuneselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. *Am J Med*. 2001;111:607-13.
- [14] Latha MM, Bhaskar MV, Sharma SSB, Sumapreethi A. Marker of oxidative stress and serum lipids in patients with polycystic ovarian syndrome. *J Evol Med Dent Sci*. 2012;1(5):769-74.
- [15] Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. *J Clin Endocrinol Metab*. 2001;86:2453-55.
- [16] de Groot PCM, Dekkers OM, Romijn JA, Dieben SWM, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. *Human Repro Update*. 2011;17(4):495-500.
- [17] Chiu WL, Boyle J, Vincent A, Teede H, Moran LJ. Cardiometabolic risks in polycystic ovary syndrome: non-traditional risk factors and the impact of obesity. *Neuroendocrinol*. 2017;104:412-24.
- [18] Saha Indranil, Paul Bobby. *Essentials of biostatistics*, 2nd edition: Academic Publishers; 2016, 64-65.
- [19] Nevill A, Holder R. Body mass index: a measure of fatness or leanness? *Brit J Nutri*. 1995;73(4):507-16.
- [20] Friedewald WT, Levy R, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. *Clin Chem*. 1972;18:499-502.
- [21] Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. *Diabetes Care*. 1999;22(2):307-13.
- [22] McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. *J Clin Endocrinol Metab*. 2001;86(2):713-18.
- [23] Romundstad S, Holmen J, Hallan H, Kvenild K, Krüger O, Midtthjell K. Microalbuminuria, cardiovascular disease and risk factors in a nondiabetic/nonhypertensive population. The Nord-Trøndelag Health Study (HUNT, 1995-97), Norway. *J Inter Med*. 2002;252(2):164-72.
- [24] Stehouwer CDA, Smulders YM. Microalbuminuria and risk for cardiovascular disease analysis of potential mechanisms. *J Am Soc Nephrol*. 2006;17:2106-11.
- [25] Basi S, Fesler P, Mimran A, Lewis JB. Microalbuminuria in Type 2 Diabetes and Hypertension A marker, treatment target, or innocent bystander? *Diabetes Care*. 2008;31(2):S194-201.
- [26] Yin J, Li M, Xu L, Wang Y, Cheng H, Zhao X, et al. Insulin resistance determined by Homeostasis Model Assessment (HOMA) and associations with metabolic syndrome among Chinese children and teenagers. *Diabetol Metabol Syndr*. 2013;5(1):71.
- [27] Li XH, Lin HY, Wang SH, Guan LY, Wang YB. Association of Microalbuminuria with Metabolic Syndrome among aged population. *Bio Med Res Int*. 2016;1-7.
- [28] Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D. Low grade albuminuria and incidence of cardiovascular disease events in non-hypertensive and non-diabetic individuals the Framingham Heart Study. *Circulation*. 2005;112:969-75.
- [29] Duleba AJ, Ahmed IM. Predictors of urinary albumin excretion in women with polycystic ovary syndrome. *Fertil Steril*. 2010;93:2285-90.
- [30] Chapman MJ, Sposito AC. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. *Pharmacol Ther*. 2008;117(3):354-73.
- [31] Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. *Cell Metabol*. 2011;14(5):575-85.
- [32] Verges B. Pathophysiology of diabetic dyslipidaemia: where are we? *Diabetologia*. 2015;58(5):886-99.
- [33] Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. *J Lipid Res*. 2009;50(Suppl):S189-94.
- [34] Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. *J Clin Endocrinol Metab*. 2008;93(2):470-76.
- [35] Tangvarasittichai S, Poonsub P, Tangvarasittichai O. Association of serum lipoprotein ratios with insulin resistance in type 2 diabetes mellitus. *Indian J Med Res*. 2010;131:641-48.
- [36] Herbst K L, Amory JK, Brunzell JD, Chansky HA, Bremner WJ. Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. *Am J Physiol Endocrinol Metab*. 2003;284(6):E1112-18.
- [37] Ambiger S. Study of insulin resistance and lipid profile in polycystic ovarian syndrome. *Int J Sci Res Pub*. 2016;6(2):1-5.
- [38] Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. *Obstet Gynecol Sci*. 2013;56(3):137-42.
- [39] Kaviprasanna S, Saikumar P, Alaguvani T. Insulin resistance as an independent risk factor for the development of dyslipidemia in polycystic ovarian syndrome. *Adv Biol Res*. 2014;8(2):53-56.

PARTICULARS OF CONTRIBUTORS:

1. Professor and Head, Department of Biochemistry, Aarupadai Veedu Medical College and Hospital, Puducherry, India.
2. Associate Professor, Department of Biochemistry, Aarupadai Veedu Medical College and Hospital, Puducherry, India.
3. Assistant Professor, Department of Biochemistry, Aarupadai Veedu Medical College and Hospital, Puducherry, India.
4. Research Scientist, Department of Central Research Lab, Aarupadai Veedu Medical College and Hospital, Puducherry, India.
5. Undergraduate, Department of Biochemistry, Aarupadai Veedu Medical College and Hospital, Puducherry, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Sasmita Mishra,
Professor and Head, Department of Biochemistry, Aarupadai Veedu Medical College and Hospital,
Kirumampakam, Puducherry-607402, India.
E-mail: mishrasasmita76@gmail.com

FINANCIAL OR OTHER COMPETING INTERESTS: None.

Date of Submission: **Jun 03, 2017**
Date of Peer Review: **Aug 05, 2017**
Date of Acceptance: **Mar 05, 2018**
Date of Publishing: **Jun 01, 2018**